What is the appropriate workup and management for a 57-year-old male with macrocytic anemia (elevated MCV), mild leukopenia, borderline high TSH while on levothyroxine for hypothyroidism, and a smoking history?

Workup and Management of Macrocytic Anemia with Leukopenia in a 57-Year-Old Male Smoker

This patient requires immediate evaluation for vitamin B12 and folate deficiency, reticulocyte count, and consideration of myelodysplastic syndrome (MDS), while optimizing his inadequate hypothyroidism treatment.

Initial Diagnostic Approach

The MCV of 127.3 fL represents significant macrocytosis that demands systematic evaluation. While hypothyroidism can cause macrocytosis, the guidelines indicate this typically produces mild elevation, not values this high 1. The combination of macrocytic anemia (hemoglobin 10.2 g/dL), leukopenia (WBC 3.4), and smoking history creates a concerning pattern requiring urgent workup.

Essential First-Line Tests

Obtain immediately:

• Reticulocyte count - This is the critical branching point in the diagnostic algorithm 1
• Vitamin B12 level - Deficiency is a leading cause of macrocytic anemia 1, 2
• Folate level - Often deficient in smokers and alcoholics 1
• Serum ferritin and transferrin saturation - To exclude concurrent iron deficiency 1
• CRP - To assess for inflammation 1
• Peripheral blood smear - Essential for detecting dysplastic features 1
• LDH and haptoglobin - If reticulocytes are elevated, to evaluate for hemolysis 1

Interpreting the Reticulocyte Count

If reticulocytes are low or normal: This indicates impaired bone marrow response, pointing toward:

• Vitamin B12 or folate deficiency (most common)
• MDS (critical concern given age, smoking, and pancytopenia) 1, 3, 4
• Hypothyroidism contribution 1

If reticulocytes are elevated: This excludes nutritional deficiencies and suggests hemolysis, which is less likely given the clinical picture 1.

Addressing the Hypothyroidism

The TSH of 3.55 mIU/L on only 25 mcg levothyroxine indicates inadequate treatment. While technically within the reference range, this patient has known hypothyroidism on a very low dose, suggesting under-replacement 5, 6.

Thyroid management:

• Increase levothyroxine dose incrementally (typically by 12.5-25 mcg) 6
• Recheck TSH in 6-8 weeks after dose adjustment 5
• Target TSH in the lower half of the reference range (0.5-2.5 mIU/L) for symptom resolution 5
• Ensure patient takes levothyroxine on empty stomach, 30-60 minutes before breakfast 6

Important caveat: While hypothyroidism can cause macrocytic anemia, it rarely produces MCV >110 fL and does not explain the leukopenia 2, 7, 8. The research shows that thyroid-related anemia is typically normocytic or mildly macrocytic 7, 9. Therefore, do not attribute this degree of macrocytosis solely to hypothyroidism.

High-Risk Features Requiring Hematology Referral

Refer to hematology if:

• MCV remains >120 fL after B12/folate repletion
• Leukopenia persists (WBC <4.0) or worsens
• Thrombocytopenia develops or platelets decline
• Peripheral smear shows dysplastic features
• B12 and folate levels are normal
• No response to vitamin supplementation within 4-8 weeks 1, 4

The combination of macrocytic anemia, leukopenia, age >50, and smoking history raises significant concern for MDS 3, 10, 4, 2. MDS is a clonal bone marrow disorder that commonly presents with macrocytic anemia and cytopenias in older adults 4.

Treatment Based on Findings

If B12 Deficiency Confirmed (most likely scenario)

• Initiate B12 replacement: 1000 mcg intramuscularly daily for 1 week, then weekly for 4 weeks, then monthly 1
• Oral high-dose B12 (1000-2000 mcg daily) is alternative if absorption intact
• Expect hemoglobin increase of ≥2 g/dL within 4-8 weeks 1
• Investigate cause: pernicious anemia, dietary deficiency, medications (PPIs, metformin)

If Folate Deficiency Confirmed

• Folic acid 1-5 mg daily orally
• Critical: Always check B12 before treating folate alone, as folate can mask B12 deficiency while allowing neurological damage to progress 1

If MDS Suspected or Confirmed

• Bone marrow aspiration and biopsy with cytogenetics required for diagnosis 3, 4
• Risk stratification using IPSS-R score 4
• Treatment ranges from supportive care to disease-modifying therapy based on risk category 3, 10, 4

Monitoring Plan

Within 2 weeks:

• Review all initial laboratory results
• Initiate vitamin replacement if deficiency confirmed

At 4-8 weeks:

• Repeat CBC to assess response to treatment
• If hemoglobin increases ≥2 g/dL, continue current therapy 1
• If no improvement, proceed to hematology referral and bone marrow evaluation

At 3 months:

• Recheck TSH and free T4 after levothyroxine dose adjustment
• Repeat CBC to confirm sustained hematological improvement

Critical Pitfalls to Avoid

1. Do not assume hypothyroidism explains this degree of macrocytosis - MCV >120 fL demands investigation beyond thyroid dysfunction 2, 8

2. Do not treat folate without checking B12 first - This can precipitate or worsen subacute combined degeneration 1

3. Do not delay hematology referral if cytopenias persist - MDS requires timely diagnosis, particularly in older smokers 3, 4

4. Do not overlook the smoking history - This significantly increases MDS risk and should lower threshold for bone marrow evaluation 4

5. Do not accept "borderline" TSH as adequate treatment - This patient on 25 mcg levothyroxine needs dose optimization 5, 6

The elevated RDW (17.0) suggests a mixed population of red cells, which can occur with combined deficiencies or early response to treatment 1. The borderline low platelets (159) warrant close monitoring, as progressive thrombocytopenia would further support MDS evaluation 4.